Pharmafile Logo

News and Press Releases

Fondazione Telethon Submits US Biological License Application for Etuvetidigene Autotemcel Gene Therapy for the Treatment of Wiskott-Aldrich Sydrome

11 March 2025 -- Milan, Italy -- Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, announced that it has submitted the Biologics License Application (BLA) for the...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 11, 2025

Fondazione Telethon
info@telethon.it
Via Poerio 14 - 20129 Milano

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2

Spikevax 2024-2025 formula expected to be available in pharmacies and care settings across the U.S. in the days immediately following approval 22 August 2024 -- Massachusetts, US -- Moderna, Inc today...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: August 22, 2024

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

ModeX Therapeutics Leverages ProBioGen’s Expertise for Accelerated COVID-19 Antibody Development

29 May 2024 -- Berlin, Germany -- ProBioGen, a leading contract development and manufacturing organisation (CDMO), known for its innovative solutions in cell engineering and bioprocessing excellence, announces a pivotal...

Category: BioManufacturing, Biotechnology, Pharmaceutical
Posted: May 29, 2024

ModeX Therapeutics
info@modextx.com
20 Riverside Road Weston, MA 02493

Veklury (remdesivir) recommended by NICE for treatment of COVID-19 in vulnerable adults and children

Remdesivir is the first antiviral treatment recommended by NICE to treat eligible children, including those with a high risk of serious illness from COVID-19 This decision secures long-term access to...

Category: Pharmaceutical
Posted: April 9, 2024

Gilead Sciences, Inc

New partnership aims to advance vaccine against MERS coronavirus

CEPI to invest up to $47m to develop and stockpile a ready reserve of emergency MERS vaccine candidate, VTP-500 VTP-500 project with Barinthus Bio and University of Oxford, UK, uses...

Category: Clinical Trials
Posted: January 2, 2024

Barinthus Biotherapeutics
Unit 6-10 Zeus Building Rutherford Avenue Harwell OX11 0DF

AstraZeneca reinforces commitment to protecting the most vulnerable from serious infectious diseases at IDWeek 2023

Real-world data from INFORM study demonstrate increased risk of severe COVID-19 outcomes among all individuals with immunocompromising conditions and highlight need for additional protection FluMist Quadrivalent data support the potential...

Category: Clinical Trials
Posted: October 12, 2023

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company’s Combination Vaccine Against Influenza and COVID-19

mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin phase 3 trial of mRNA-1083 in adults...

Category: Clinical Trials, Drug Discovery
Posted: October 4, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

New exploratory analysis of phase 3 SCORPIO-SR study data in Asia suggests that ensitrelvir may reduce the risk of persistent and new late-onset symptoms associated with long COVID-19 over one...

Category: Clinical Trials
Posted: September 20, 2023

SHIONOGI
contact@shionogi.eu
33 Kingsway, London, WC2B 6UF, UK

MODERNA RECEIVES US FDA APPROVAL FOR UPDATED COVID-19 VACCINE

Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86 Updated vaccine to be available in pharmacies and care settings across the US in the...

Category: Clinical Trials
Posted: September 12, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139

NIH and Exothera collaborate to produce GMP intranasal vaccine against SARS-CoV-2 for clinical phase I/II trial in Africa and US

16 August 2023 -- Maryland, US and Jumet, Belgium -- The National Institutes of Health (NIH), the US’s medical research agency, selected Exothera, a full-service Contract Development and Manufacturing Organisation...

Category: Other
Posted: August 23, 2023

Exothera
Zoning de Jumet, Allée Centrale 52, 6040 Jumet - BELGIUM

MODERNA CLINICAL TRIAL DATA CONFIRMS ITS UPDATED COVID-19 VACCINE GENERATES ROBUST IMMUNE RESPONSE IN HUMANS AGAINST WIDELY CIRCULATING VARIANTS 

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant  Updated vaccine expected to be available, pending approval, in coming weeks...

Category: Other
Posted: August 22, 2023

Moderna
info@modernatx.com
Global Headquarters 200 Technology Square Cambridge, MA 02139